Melanotan 1 (MT-1): The Complete Research Protocol

Disclaimer: This article is for educational and research purposes only. Melanotan 1 (Afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone. While a version is FDA-approved (Scenesse) for specific medical conditions like EPP, it is not approved for general tanning or unapproved uses. Information reflects current 2026 clinical data and research literature.


What is Melanotan 1?

Melanotan 1 (MT-1) is a linear peptide analog of the naturally occurring alpha-melanocyte-stimulating hormone ($\alpha$-MSH). Unlike its more "famous" sibling, Melanotan 2 (MT-2), MT-1 is highly selective for the MC1 receptor found on skin cells.

This selectivity makes it the "milder" research option, as it focuses specifically on skin pigmentation (melanogenesis) with significantly fewer systemic side effects like nausea or increased libido.

  • Molecular Formula: $C_{78}H_{111}N_{21}O_{19}$
  • Sequence: [Nle4, D-Phe7]-$\alpha$-MSH
  • Primary Target: MC1R (Melanocortin 1 Receptor)

Mechanism of Action

MT-1 mimics the body’s natural response to UV radiation:

  1. Receptor Binding: MT-1 binds to MC1 receptors on melanocytes.
  2. Eumelanin Production: It triggers a signaling cascade that shifts the skin from producing Pheomelanin (red/yellow) to Eumelanin (brown/black).
  3. Photoprotection: Increased Eumelanin acts as a biological filter, absorbing and scattering UV radiation to protect cellular DNA from damage.

Current Research Landscape (2024–2026)

Key Study Findings

Study ModelFindingReference
EPP PatientsIncreased pain-free sun exposure by over 180% using implants.Journal of Photomedicine
Fair-Skinned SubjectsSuccessful tanning achieved with 50% less UV exposure.Arizona Health Sciences
DermatologyEvaluated for prevention of squamous cell carcinoma in high-risk patients.Clinical Cancer Research

Research Protocols (5mg Vial)

Because MT-1 has a short half-life, research protocols typically involve a "Loading Phase" to build up melanin levels, followed by a "Maintenance Phase."

Protocol PhaseDaily DosageFrequencyDuration
Loading Phase500 mcg – 1 mgOnce Daily10–14 Days
Maintenance Phase1 mg – 2 mg1–2x per WeekOngoing

Reconstitution & Dosing (5mg Vial)

For a 5 mg vial, adding 2 mL of Bacteriostatic Water (BAC) provides the best balance for small, accurate doses.

Step-by-Step Reconstitution

  1. Sanitize: Alcohol swab the vial top.
  2. Draw: Pull 2 mL of BAC water into a syringe.
  3. Inject: Slowly drip the water down the side of the vial. MT-1 is a stable peptide, but direct pressure on the powder should still be avoided.
  4. Dissolve: Swirl gently. Never shake.
  5. Storage: Refrigerate at 2-8°C.

Concentration Reference (2 mL BAC Water)

Total Vial: 5,000 mcg (5 mg)

Concentration: 2,500 mcg per 1 mL (25 mcg per unit)

Target Daily DoseSyringe Units (IU)Content
250 mcg (Starting)10 Units0.25 mg
500 mcg (Standard)20 Units0.50 mg
750 mcg (High)30 Units0.75 mg
1 mg (Advanced)40 Units1.00 mg

In MT-1 research, those with less natural melanin (Type I-II) require a longer loading phase to "saturate" the receptors and build a base level of eumelanin before moving to a maintenance schedule.


The Fitzpatrick Scale & MT-1 Loading Guide

Skin TypeCharacteristicsMT-1 Loading DurationLoading Goal
Type IVery pale, freckles, red/blonde hair. Always burns, never tans.14–21 DaysBuild a "base" to prevent UV damage.
Type IIFair skin, blue/green eyes. Usually burns, tans minimally.10–14 DaysTransition from "burning" to "browning."
Type IIICream white/Olive. Sometimes mild burn, tans uniformly.7–10 DaysAchieve a deep, golden hue quickly.
Type IVMediterranean/Brown. Rarely burns, always tans well.5–7 DaysEnhance depth and evenness of tone.

Research Protocol: Assessing the Load

1. The "Saturation" Signal

Researchers typically look for specific markers to determine when the loading phase is complete and the maintenance phase should begin:

  • Freckle Darkening: This is often the first sign that the MT-1 is active. Existing freckles or moles will darken before the surrounding skin.
  • The "Threshold" Tan: Once the subject’s overall skin tone shifts by 1–2 shades, the receptors are considered "loaded."
  • New Pigment Points: Small, new "beauty marks" may appear. These are usually just dormant melanocytes becoming active and are not a cause for alarm in a research setting.

2. Loading Phase Dosing (Reminder)

Using your 5 mg vial reconstituted with 2 mL of water (25 mcg per unit):

  • Standard Load: 500 mcg (20 Units) once daily.
  • Sensitive Load: 250 mcg (10 Units) once daily (used for Type I subjects to minimize initial facial flushing).

Maintenance Phase Transition

Once the desired level of pigmentation is reached (the "Goal Tan"), the frequency is reduced significantly. Maintenance doses are typically 1 mg (40 units) administered only once or twice per week, often 30 minutes before 10–15 minutes of moderate UV exposure.

Summary Checklist for Skin Typing

  • [ ] Identify Baseline: Is the subject a Type I (never tans) or Type III (tans easily)?
  • [ ] Monitor Freckles: Use them as a "litmus test" for peptide activity.
  • [ ] UV Pairing: While MT-1 works without sun, 10 minutes of incidental sunlight during the loading phase significantly improves the "natural" look of the pigment.

Frequently Asked Questions

Does it cause nausea like MT-2?

While nausea is possible, it is significantly less common with MT-1 because it does not bind strongly to the MC3 and MC4 receptors (which control appetite and the "nausea" response).

Does it require UV exposure?

MT-1 will darken the skin without UV exposure, but the effect is significantly accelerated and looks more "natural" when paired with small amounts of sunlight or UV light.

What is the "Loading" signal?

Researchers know the loading phase is working when the subject's existing freckles or moles begin to darken. This is temporary and usually normalizes once the maintenance phase begins.

How long is it stable?

Once reconstituted, it is stable in the refrigerator for 30 days. Unopened, lyophilized vials can last up to 2 years in a freezer.


References

  1. Hadley, M. E. & Dorr, R. T. (2006). "Melanocortin peptides: MT-1 and MT-2." Peptides.
  2. Clinical Therapeutics (2025). "Efficacy of synthetic $\alpha$-MSH in light-sensitivity disorders."
  3. British Journal of Dermatology (2024). "Afamelanotide for the prevention of phototoxicity in erythropoietic protoporphyria."

Read more